(MedPage Today) — SAN FRANCISCO — For patients with recurrent prostate cancer, those with a certain subtype had clinically meaningful benefits when apalutamide (Erleada) was added to salvage radiotherapy after radical prostatectomy, a randomized…
(MedPage Today) — SAN FRANCISCO — For patients with recurrent prostate cancer, those with a certain subtype had clinically meaningful benefits when apalutamide (Erleada) was added to salvage radiotherapy after radical prostatectomy, a randomized…